AMC NETWORKS INC. REPORTS THIRD QUARTER 2025 RESULTS New York, NY – November 7, 2025: AMC Networks Inc. ("AMC Networks" or the "Company") (NASDAQ: AMCX) today reported financial results for the third quarter ended September 30, 2025. Chief Executive Officer Kristin Dolan said: "Our performance in the third quarter marks a key milestone in our transition from a cable networks business to a global streaming and technology focused content company. Streaming revenue growth accelerated and will represent our lar ...

Financial Performance - Total revenues for Q3 2025 reached $228,587,000, a 7.5% increase from $211,795,000 in Q3 2024[18] - Net income attributable to EVERTEC, Inc.'s common stockholders for Q3 2025 was $32,861,000, compared to $24,678,000 in Q3 2024, reflecting a 33.5% year-over-year growth[18] - Operating income for Q3 2025 was $37,732,000, down from $41,541,000 in Q3 2024, reflecting a decrease of 9.0%[18] - The company reported a total comprehensive income of $46,146,000 for Q3 2025, compared to $28,094,000 in Q3 2024, an increase of 64.3%[18] - Net income for the quarter ending September 30, 2025, was $32,700,000, compared to $40,404,000 for the previous quarter[20] - Net income for the nine months ended September 30, 2025, was $107,524,000, an increase of 45% compared to $74,112,000 in 2024[23] - Net income available to common shareholders for the nine months ended September 30, 2025, was $106.029 million, compared to $72.558 million for the same period in 2024, reflecting a growth of approximately 46%[96] Assets and Liabilities - Total assets increased to $2,149,167,000 as of September 30, 2025, up from $1,857,611,000 at the end of 2024, representing a 15.6% growth[17] - Current assets rose to $744,420,000, a significant increase from $529,065,000 at the end of 2024, marking a 40.7% increase[17] - Long-term debt increased to $1,059,143,000 from $925,062,000, indicating a 14.5% rise[17] - Total stockholders' equity grew to $663,750,000 as of September 30, 2025, compared to $472,524,000 at the end of 2024, a 40.4% increase[17] - As of September 30, 2025, total debt amounted to $1,095,751,000, an increase of 13.5% from $965,343,000 on December 31, 2024[47] Cash Flow and Dividends - Cash and cash equivalents increased to $474,738,000 from $273,645,000, a growth of 73.5%[17] - Cash dividends declared on common stock were $3,199,000 for the quarter ending September 30, 2025, consistent with the previous quarters[20] - The company paid $47,477,000 in interest for the nine months ended September 30, 2025, down from $55,024,000 in 2024[123] - The Company declared quarterly cash dividends of $0.05 per share on February 20, May 2, and July 24, 2025, totaling $0.15 per share for the year[97] Acquisitions and Investments - The company completed the acquisition of Grandata, Inc. for $33.3 million, enhancing its product offerings in data analytics[37] - The acquisition of Nubity, Inc. was finalized for $11.0 million, focusing on cloud services and infrastructure management[38] - On October 1, 2025, the company acquired 75% of Tecnobank for BRL$787 million (approximately USD$148 million), enhancing its product offerings[124][125] - The Company purchased the remaining interest of approximately 40% in Homie Do Brasil Informatica for $5.2 million, classified as a financing activity[66] Segment Performance - The Payment Services - Puerto Rico & Caribbean segment generated revenues of $36.7 million, while the Latin America Payments and Solutions segment contributed $83.4 million, indicating strong performance across these segments[110] - Segment Adjusted EBITDA for the total reportable segments was $98.0 million for the three months ended September 30, 2025, compared to $92.8 million for the same period in 2024, reflecting an increase of about 5.5%[110] - The Merchant Acquiring segment's revenues included discount fees and membership fees charged to merchants, contributing significantly to the overall revenue growth[105] - The Business Solutions segment reported revenues driven by a full suite of business process management solutions, with a focus on core bank processing and managed services[106] - The Latin America Payments and Solutions segment's revenues are primarily driven by transaction processing, highlighting the importance of transaction volume in revenue generation[104] Expenses and Costs - The company experienced a decrease in depreciation and amortization expenses to $28,435,000 in Q3 2025 from $33,660,000 in Q3 2024, a reduction of 15.6%[18] - The company reported a decrease in depreciation and amortization expenses to $85,217,000 from $101,051,000, a reduction of approximately 16%[23] - Amortization expense for other intangibles for the nine months ended September 30, 2025 was $68.7 million, down from $84.2 million for the same period in 2024, indicating a decrease of 18.4%[45] Tax and Regulatory - As of September 30, 2025, the gross deferred tax asset was $98.4 million, while the gross deferred tax liability was $87.2 million, compared to $74.3 million and $79.9 million, respectively, as of December 31, 2024[93] - The current tax provision for the nine months ended September 30, 2025, was $27.119 million, an increase from $23.375 million in 2024[91] Other Financial Metrics - The balance of accumulated other comprehensive loss improved from $(134,723) at December 31, 2024, to $(48,374) at September 30, 2025[68] - The estimated aggregate amount of the transaction price allocated to unsatisfied or partially satisfied performance obligations was $724.8 million, expected to be recognized over the next 5 to 7 years[85] - The allowance for expected current credit losses on trade receivables was $2.619 million as of September 30, 2025, down from $2.856 million at the end of 2024[88] - A hypothetical 100 basis point increase in interest rates would increase annual interest expense by approximately $5.5 million based on outstanding debt as of September 30, 2025[209] - The company has three interest rate swap agreements to convert a portion of variable rate debt to fixed[210]

Revenue Performance - Operating revenue decreased by $59.7 million, or 8.1%, in the first nine months of 2025 compared to the same period in 2024[62] - Truckload segment revenue, net of fuel surcharges, decreased by 4.1% primarily due to a decrease in average fleet size, despite an increase in average revenue per tractor[62] - Dedicated segment revenue, net of fuel surcharges, decreased by 10.7% from the first nine months of 2024, also due to a decrease in average fleet size[62] - Intermodal segment revenue, net of fuel surcharges, decreased by 24.8% from the first nine months of 2024, attributed to decreases in both the number of loads and revenue per load[62] - Operating revenue decreased by $16.9 million, or 7.1%, to $220.5 million in the 2025 period from $237.4 million in the 2024 period[69] - Truckload segment revenue decreased by $3.6 million, or 3.3%, to $104.8 million in the 2025 period from $108.4 million in the 2024 period[70] - Dedicated segment revenue decreased by $8.0 million, or 10.7%, to $67.0 million in the 2025 period from $75.0 million in the 2024 period[71] - Intermodal segment revenue decreased by $4.7 million, or 32.1%, to $9.9 million in the 2025 period from $14.5 million in the 2024 period[72] - Total operating revenue decreased by $59.7 million, or 8.1%, to $673.5 million in the 2025 period from $733.3 million in the 2024 period[87] - Truckload segment revenue decreased $16.8 million, or 5.1%, to $315.7 million in the 2025 period from $332.5 million in the 2024 period[88] - Dedicated segment revenue decreased $30.2 million, or 12.5%, to $212.5 million in the 2025 period from $242.7 million in the 2024 period[89] - Intermodal segment revenue decreased $11.9 million, or 26.1%, to $33.7 million in the 2025 period from $45.5 million in the 2024 period[90] - Brokerage segment revenue decreased $828,000, or 0.7%, to $111.7 million in the 2025 period from $112.5 million in the 2024 period[91] Income and Profitability - Operating income declined by 30.8% to $18.3 million in the first nine months of 2025 from $26.5 million in the same period of 2024[64] - Net income decreased by 35.4% to $13.7 million, or $0.17 per diluted share, in the first nine months of 2025 compared to $21.3 million, or $0.26 per diluted share, in the first nine months of 2024[64] - Total operating income decreased by $1.5 million, or 35.9%, to $2.7 million in the 2025 period from $4.3 million in the 2024 period[75] - Net income decreased by $1.5 million, or 40.7%, to $2.2 million in the 2025 period from $3.7 million in the 2024 period[75] - Operating income declined 35.9% to $2.7 million in the 2025 period from $4.3 million in the 2024 period[83] - Net income decreased 40.7% to $2.2 million, or $0.03 per diluted share, in the 2025 period from $3.8 million, or $0.05 per diluted share, in the 2024 period[86] Cash Flow and Capital Expenditures - Cash and cash equivalents increased by $37.2 million in the first nine months of 2025, with $54.5 million in cash and cash equivalents at September 30, 2025[65] - Capital expenditures for the remainder of 2025 are estimated to be approximately $28 million[65] - Net cash flows provided by operating activities were $87.9 million in the first nine months of 2025, down from $111.0 million in the same period of 2024[105] - Capital expenditures for the remainder of 2025 are estimated to be approximately $28 million, including commitments to purchase $32.9 million of new revenue equipment[106] Operating Ratios and Expenses - Operating ratio for Truckload increased to 101.9% in the 2025 period from 100.1% in the 2024 period[70] - Operating ratio for Dedicated improved to 94.9% in the 2025 period from 95.9% in the 2024 period[71] - Operating expenses decreased by $51.6 million, or 7.3%, in the 2025 period compared to the 2024 period[92] - Fuel and fuel taxes decreased by $2.3 million, or 6.3%, in the 2025 period from the 2024 period[78] - Fuel and fuel taxes decreased by $14.9 million, or 13.1%, in the 2025 period from the 2024 period[94] - The operating ratio for the Truckload segment was 100.0% in 2025, compared to 99.6% in 2024[98] Tax and Compliance - The effective income tax rate increased to 28.9% in 2025 from 27.2% in 2024[99] - The company was in compliance with all covenants of its credit agreement as of September 30, 2025[108] Shareholder Returns - The company has not repurchased any shares since the second quarter of 2022, with future repurchases of up to $33.2 million available[104] - The company expects to continue paying quarterly cash dividends of $0.06 per share, totaling $14.7 million in each of the first three quarters of 2025 and 2024[106] Equipment Disposition - Gain on disposition of revenue equipment increased to $1.9 million in the 2025 period from $881,000 in the 2024 period[82] - Gain on disposition of revenue equipment increased to $8.8 million in the 2025 period from $4.6 million in the 2024 period[97] Revenue per Tractor - Average revenue per tractor per week for the Truckload segment was $4,178 in the first nine months of 2025, compared to $4,090 in the same period of 2024[68] - Average revenue per tractor per week for the Dedicated segment increased to $3,811 in the first nine months of 2025 from $3,744 in the same period of 2024[68] Fuel Cost Impact - A 5% increase in the average cost of diesel fuel would have increased fuel expenses by $4.8 million in the first nine months of 2025[113]

Financial Performance - Revenues for the three months ended September 30, 2025, were $733,773,000, a 33.3% increase from $550,344,000 in the same period of 2024[115] - Gross profit for the same period was $337,409,000, representing a gross profit margin of 46%, up from 42% in 2024[115] - Operating income increased to $261,722,000, which is 35% of revenues, compared to 31% in the prior year[115] - Net income for the three months ended September 30, 2025, was $207,876,000, or 28% of revenues, compared to $127,988,000, or 23% of revenues in 2024[115] - Total revenues increased by $183.4 million, or 33%, from $550.3 million in Q3 2024 to $733.8 million in Q3 2025[116] Revenue Breakdown - Sales to distributors accounted for 57% of total revenues, while direct sales made up 43% during the three months ended September 30, 2025[104] - Enterprise Technology revenue rose by $187.0 million, or 40%, from $470.2 million in Q3 2024 to $657.1 million in Q3 2025, accounting for 90% of total revenues[117] - Service Provider Technology revenue decreased by $3.5 million, or 4%, from $80.2 million in Q3 2024 to $76.6 million in Q3 2025[118] - North America revenues increased by $111.6 million, or 41%, from $271.2 million in Q3 2024 to $382.8 million in Q3 2025[121] Expenses - Research and development expenses were $48,543,000, maintaining 7% of revenues, while sales, general and administrative expenses were $27,144,000, also 4% of revenues[115] - R&D expenses increased by $10.5 million, or 28%, from $38.0 million in Q3 2024 to $48.5 million in Q3 2025, remaining at 7% of revenues[126] - SG&A expenses increased by $2.7 million, or 11%, from $24.4 million in Q3 2024 to $27.1 million in Q3 2025, consistent at 4% of revenues[128] - Interest expense decreased by $7.4 million, or 70%, from $10.6 million in Q3 2024 to $3.2 million in Q3 2025, reducing its percentage of revenue from 2% to 0.4%[130] - Provision for income taxes increased by $20.0 million, or 65%, from $30.6 million in Q3 2024 to $50.7 million in Q3 2025, with an effective tax rate of 19.6%[132] Cash and Commitments - Cash and cash equivalents increased to $177.2 million as of September 30, 2025, up from $149.7 million as of June 30, 2025[134] - As of September 30, 2025, the company had $1,249.8 million in purchase commitments with third-party manufacturers[150] - The company reported other obligations of $4.9 million primarily related to research and development projects as of September 30, 2025[151] - The company had $34.7 million in unrecognized tax benefits and an additional $6.0 million for accrued interest classified as non-current liabilities as of September 30, 2025[154] Risks and External Factors - The company has experienced increased costs due to tariffs imposed on imports, which are expected to continue affecting operating results and margins[97] - Supply constraints have led to increased inventory and vendor deposit balances, impacting future material excess and obsolete inventory risks[98] - The ongoing geopolitical tensions, including the Russia-Ukraine conflict and China-Taiwan tensions, are being monitored for their potential impact on operations and supply chains[99][100] Currency and Interest Rate Sensitivity - A 200-basis-point increase in interest rates would result in an incremental charge of approximately $2.7 million to income before income taxes over the next twelve months[158] - A 10% change in foreign currency exchange rates could result in a charge or benefit of approximately $3.2 million to income before income taxes for the three months ended September 30, 2025[159] - The company may face a charge or benefit of approximately $4.4 million due to fluctuations in foreign currency exchange rates for bank accounts as of September 30, 2025[160]

NEWS RELEASE Enbridge Reports Strong Third Quarter Results, Announces Accretive Investments and Reaffirms 2025 Financial Guidance (All financial figures are unaudited and in Canadian dollars unless otherwise noted. * identifies non-GAAP financial measures. Please refer to Non-GAAP Reconciliations Appendices.) 1 • Third quarter GAAP earnings attributable to common shareholders of $0.7 billion or $0.30 per common share, compared with GAAP earnings attributable to common shareholders of $1.3 billion or $0.59 p ...

Exhibit 99.1 News Release Contact: Linsey Wisniewski Corporate Communications 667-218-7700 Emily Duncan Investor Relations 833-447-2783 CONSTELLATION REPORTS THIRD QUARTER 2025 RESULTS Earnings Release Highlights Baltimore (Nov 7, 2025) — Constellation Energy Corporation (Nasdaq: CEG) today reported its financial results for the third quarter of 2025. "We achieved one of the highest operating quarters for our nuclear fleet and advanced major milestones like our historic settlement with Maryland for continue ...

Market Overview - The global market for peripheral vascular devices exceeds $5 billion, with the company's product market estimated at approximately $1 billion[75]. - In Q3 2025, biologics accounted for 54% of worldwide sales, indicating a strong focus on this product segment[78]. - The company expects to hold 22 CE and UKCA approvals by the end of 2025, covering nearly all product offerings in the EU and UK[85]. Sales Performance - Net sales increased by $6.2 million, or 11%, to $61.0 million for the three months ended September 30, 2025, compared to $54.8 million for the same period in 2024[99]. - For the nine months ended September 30, 2025, net sales increased by $21.0 million, or 13%, to $185.1 million, compared to $164.1 million for the same period in 2024[103]. - Direct-to-hospital net sales accounted for 95% of total net sales for both the three and nine months ended September 30, 2025, and 2024[102][104]. - Net sales in the Americas increased by $3.4 million, or 10%, for the three months ended September 30, 2025, compared to the same period in 2024[104]. - EMEA net sales increased by $2.6 million, or 18%, for the three months ended September 30, 2025, compared to the same period in 2024[106]. - APAC net sales increased by $0.7 million, or 6%, for the nine months ended September 30, 2025, compared to the same period in 2024[109]. Financial Metrics - Gross profit for the three months ended September 30, 2025, increased by $8.8 million, or 24%, to $46.0 million, with a gross margin of 75.3%, up from 67.8% in 2024[111]. - For the nine months ended September 30, 2025, the company reported an operating income of $49.1 million, an increase from $39.4 million for the same period in 2024[134]. - Cash and cash equivalents as of September 30, 2025, were $25.5 million, slightly down from $25.6 million as of December 31, 2024[127]. - Net cash provided by operating activities was $58.1 million for the nine months ended September 30, 2025, compared to $28.9 million for the same period in 2024[136][137]. - Net cash used in investing activities was $48.1 million for the nine months ended September 30, 2025, primarily due to purchases of marketable securities totaling $43.0 million[140]. Expenses - Sales and marketing expenses increased by 20% to $41.0 million for the nine months ended September 30, 2025, driven by higher sales representative headcount and wage increases[114]. - General and administrative expenses increased by 18% to $31.6 million for the nine months ended September 30, 2025, primarily due to higher headcount and wage increases[116]. - Research and development expenses decreased by 12% to $10.6 million for the nine months ended September 30, 2025, driven by lower third-party service fees[119]. Strategic Decisions - The company aims to grow its direct sales force and increase average selling prices of devices as part of its business strategy[80]. - The decision to wind down certain product lines resulted in approximately $2.2 million in revenues in 2021 and $0.7 million in 2022[86]. - The transition to direct sales in various countries, including Korea and Thailand, involved termination fees totaling approximately $1.2 million[91]. Regulatory and Taxation - The company received regulatory approvals for multiple products, including the XenoSure patch in Japan and the Artegraft bovine graft in the EU, enhancing market access[84][85]. - The effective income tax rate for the three months ended September 30, 2025, was 23.0%, compared to 23.4% for the same period in 2024[120][121]. - The company recorded a tax provision of $5.2 million on pre-tax income of $22.6 million for Q3 2025, up from a $3.4 million provision on pre-tax income of $14.6 million in Q3 2024[120]. Capital and Dividends - The company authorized a stock repurchase program of up to $75.0 million, which may be executed until February 17, 2026[128]. - The company issued $172.5 million in convertible senior notes due 2030, with a net proceeds of approximately $167.7 million after debt issuance costs[129][130]. - The Board of Directors approved a quarterly cash dividend of $0.20 per share for Fiscal Year 2025, totaling $4,517,000 for the payment on March 27, 2025[144]. - For Fiscal Year 2024, the quarterly cash dividend was $0.16 per share, with total payments of $3,589,000, $3,593,000, $3,596,000, and $3,600,000 for each quarter[144]. Accounting Policies - The company has not made any material changes to its critical accounting policies and estimates as disclosed in the 2024 Form 10-K[146]. - There are no significant changes in foreign currency risk or interest rate risk from the previous disclosures in the 2024 Form 10-K[148].

Acquisition and Expansion - On September 16, 2024, the company completed the acquisition of Alimera Sciences, adding the ILUVIEN® and YUTIQ® products to its portfolio, which are approved for treating diabetic macular edema and non-infectious uveitis, respectively[210]. - The acquisition of Alimera is expected to strengthen the Rare Disease business and expand the company's footprint in Europe, Asia, and the Middle East[214]. - The company incurred approximately $13.2 million in transaction and integration costs related to the Alimera acquisition during the nine months ended September 30, 2024[226]. - The company plans to continue expanding its Rare Disease business through organic growth and acquisitions, focusing on niche opportunities[215]. - The company repaid $72.5 million of Alimera's debt as part of the merger[223]. - Each contingent value right (CVR) from the Alimera acquisition entitles holders to milestone payments based on net revenues exceeding $140 million in 2026 and $160 million in 2027[224]. - The company extended its partnership with Alliance Medical Products, Inc. to support the transition to ILUVIEN and expanded manufacturing capacity through the addition of a second manufacturing line[216]. Financial Performance - Net revenues for Q3 2025 were $227.8 million, a 53.6% increase from $148.3 million in Q3 2024, driven by growth in Rare Disease and Brands[238]. - Rare Disease total net revenues reached $118.5 million in Q3 2025, up 109.9% from $56.4 million in Q3 2024, primarily due to increased sales of Cortrophin Gel and a full quarter of sales from ILUVIEN[236]. - Operating income for Q3 2025 was $36.2 million, compared to a loss of $20.5 million in Q3 2024, marking a substantial turnaround[234]. - Net income for Q3 2025 was $26.6 million, compared to a loss of $24.2 million in Q3 2024, indicating a significant improvement in profitability[234]. - For the three months ended September 30, 2025, total net revenue was $636.3 million, an increase of 50.1% compared to $423.8 million for the same period in 2024[253]. - Rare Disease total net revenues reached $291.4 million, up 104.4% from $142.6 million in the same period last year, driven by increased volume of Cortrophin Gel and sales from ILUVIEN and YUTIQ[253]. Expenses and Costs - Cost of sales for Q3 2025 increased to $93.4 million, a 48.1% rise from $63.1 million in Q3 2024, attributed to significant growth in sales volumes[240]. - Research and development expenses increased by 21.5% to $12.3 million in Q3 2025 from $10.1 million in Q3 2024[244]. - Selling, general, and administrative expenses decreased by 3.1% to $76.7 million in Q3 2025 from $79.1 million in Q3 2024[244]. - The cost of sales as a percentage of net revenues decreased to 41.0% in Q3 2025 from 42.5% in Q3 2024, primarily due to the non-recurrence of inventory step-up costs[241]. - Cost of sales increased to $241.0 million, a rise of 41.8% from $169.9 million in the prior year, attributed to significant growth in sales volumes[257]. - Total other operating expenses increased to $318.9 million for the nine months ended September 30, 2025, up from $248.9 million in 2024, representing a 28.1% increase[259]. - Research and development expenses rose to $39.4 million, a 41.1% increase from $27.9 million in 2024, driven by ongoing and new projects in Rare Disease and Generics[259]. - Selling, general, and administrative expenses increased by 30.6% to $235.0 million from $179.9 million, primarily due to higher employment costs and investments in Rare Disease sales and marketing[259]. - Depreciation and amortization expenses were $68.8 million, up 52.5% from $45.1 million, mainly due to amortization of acquired intangible assets ILUVIEN and YUTIQ[259]. Cash Flow and Financing - Net cash provided by operating activities was $154.9 million for the nine months ended September 30, 2025, an increase of $106.7 million compared to $48.2 million in the same period of 2024[284]. - Net cash used in investing activities for the nine months ended September 30, 2025 was $32.9 million, significantly lower than $394.0 million in the same period of 2024, primarily due to the acquisition of Alimera[285]. - Net cash used in financing activities for the nine months ended September 30, 2025 was $5.3 million, compared to $269.9 million provided in the same period of 2024[286]. - The company entered into a new credit agreement providing for a senior secured term loan facility of $325.0 million and a revolving credit facility of $75.0 million[265]. - The company drew the full $325.0 million of Term Loan A on September 16, 2024, to finance the acquisition of Alimera[266]. - The company issued $275.0 million of Convertible Senior Notes due 2029, with net proceeds of approximately $306.8 million used to repay existing senior secured credit agreements[270]. - The cash interest rate under the Term Loan A was approximately 6.76% as of September 30, 2025[266]. - The Company believes its financial resources will be sufficient to meet working capital requirements and debt obligations for at least the next 12 months[282]. Tax and Other Financial Metrics - The effective tax rate for the three months ended September 30, 2025, was 21.3%, with an income tax expense of approximately $7.2 million[250]. - An income tax expense of approximately $13.5 million was recorded for the nine months ended September 30, 2025, with an effective tax rate of 20.9%[263]. - The company recognized a gain of $14.5 million for contingent consideration fair value adjustments during the three months ended September 30, 2025[247]. - Interest expense, net increased by $2.4 million, primarily due to higher interest expenses related to the New Credit Agreement and Convertible Senior Notes[252]. - The company recorded an unrealized gain on investment in equity securities of approximately $3.1 million for the three months ended September 30, 2025[252]. - Cost of sales as a percentage of net revenues decreased to 37.9% from 40.1% year-over-year, reflecting a shift in product mix[258]. - The Company paid an upfront payment of $75.0 million to EyePoint for a product rights agreement, with additional quarterly payments totaling $7.5 million during 2024[280]. - The Company expects to pay royalties to EyePoint at 30% of annual U.S. net sales of certain products starting at $70.0 million in 2025, increasing annually thereafter[281]. - The Company used approximately $40.6 million of the net proceeds from the offering of the Notes to pay premiums on the Capped Calls[277]. - The Capped Calls cover approximately 4.3 million shares of the Company's common stock, aimed at reducing potential dilution upon conversion of the Notes[278].

Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance PRINCETON, N.J., November 7, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the third quarter ended September 30, 2025. "ANI had another strong quarter in which we delivered record revenue and adjusted EBITDA, underscoring the strength of our Rare Disease and Generics business ...

F e b ru a ry 7 , 2 0 2 3 KKR Reports Third Quarter 2025 Financial Results New York, November 7, 2025 – KKR & Co. Inc. (NYSE: KKR) today reported its third quarter 2025 results. KKR KKR & Co. Inc. Reports Third Quarter 2025 Financial Results K K R & C o. I n c. R e p o r t s T h i r d Q u a r t e r 2 0 2 5 F i n a n c i a l R e s u l t s N o v e m b e r 7 , 2 0 2 5 Conference Call A conference call to discuss KKR's financial results will be held on November 7, 2025 at 9:00 a.m. ET. The conference call may b ...